Business Description
Ocumension Therapeutics
ISIN : KYG674111011
Share Class Description:
OCUTF: Ordinary SharesTotal Employee Number:
552Compare
Compare
Traded in other countries / regions
01477.Hong KongOCUTF.USA5DG.Germany IPO Date
2021-06-22Description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.92 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -16.1 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.76 | |||||
Beneish M-Score | -1.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 58.7 | |||||
3-Year EBITDA Growth Rate | 70.1 | |||||
3-Year EPS without NRI Growth Rate | 31.9 | |||||
3-Year FCF Growth Rate | 17.8 | |||||
3-Year Book Growth Rate | 4.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 35.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.7 | |||||
Quick Ratio | 3.46 | |||||
Cash Ratio | 2.13 | |||||
Days Inventory | 47.85 | |||||
Days Sales Outstanding | 101.64 | |||||
Days Payable | 31.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | -2.91 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 44.91 | |||||
Operating Margin % | -19.36 | |||||
Net Margin % | -19.65 | |||||
EBITDA Margin % | -1.45 | |||||
FCF Margin % | -44.4 | |||||
OCF Margin % | -12.95 | |||||
ROE % | -4.32 | |||||
ROA % | -4.01 | |||||
ROIC % | -4.8 | |||||
3-Year ROIIC % | 17.53 | |||||
ROC (Joel Greenblatt) % | -26.77 | |||||
ROCE % | -4.13 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.37 | |||||
PB Ratio | 0.97 | |||||
Price-to-Tangible-Book | 3.33 | |||||
EV-to-EBIT | -20.57 | |||||
EV-to-EBITDA | -272.99 | |||||
EV-to-Revenue | 3.97 | |||||
EV-to-FCF | -8.92 | |||||
Price-to-GF-Value | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 6.36 | |||||
| Price-to-Net-Cash | 23.33 | |||||
Earnings Yield (Greenblatt) % | -4.86 | |||||
FCF Yield % | -10.02 |
Ocumension Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ocumension Therapeutics Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Guru Commentaries on OTCPK:OCUTF
No articles.
Articles on Ocumension Therapeutics
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers